XmAb 7195

Drug Profile

XmAb 7195

Alternative Names: XmAb® 7195

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xencor
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIB antagonists; IgE receptor antagonists; Immunoglobulin E inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic asthma; Hypersensitivity

Highest Development Phases

  • Phase I Allergic asthma; Hypersensitivity

Most Recent Events

  • 07 Nov 2017 XmAb 7195 is available for licensing as of 07 Nov 2017. www.xencor.com
  • 07 Nov 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Allergic asthma and Hypersensitivity released by Xencor
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-asthma in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top